(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem - 2Believe Should Unwind? Look at These Scaled down Games
- 3Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- 4ChatGPT served as "suicide coach" in man's death, lawsuit alleges
- 5Burkina Faso must 'forget' about democracy, military leader says
- Current Chateaus: Advancement and Style
- New nesting beach for birds at RSPB reserve
- Soldiers seize power in Guinea-Bissau and detain the president
- RFK Jr. says he's following 'gold standard' science. Here's what to know
- Wedding trip Objections in Europe
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Sun storms are powered by a magnetic engine 16 Earths deep, study finds
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- The Force of Mentorship: Self-improvement through Direction
